State Initiatives

AAM Statement on U.S. Court of Appeals Ruling on Maryland HB 631

WASHINGTON, DC (April 13, 2018) — Today, the United States Court of Appeals for the Fourth Circuit ruled that Maryland’s HB 631 is unconstitutional because it violates the Commerce Clause of the U.S. Constitution. As AAM has always maintained, this law, and any others modeled from it, would harm patients because the law would reduce generic drug competition and choice, thus resulting in an overall increase in drug costs due to increased reliance upon more-costly branded medications.

Chester "Chip" Davis, Jr. President and CEO, Association for Accessible Medicines

Oppose Illinois House Bill 4900

Everyone supports containing skyrocketing prescription drug prices but HB 4900, sponsored by Rep. Will Guzzardi (D-Chicago), would actually just make the problem worse for Illinois patients. Price gouging– targeted by this bill – is unacceptable. But we must employ sound public policy to both weed out bad apples and enhance a market where they cannot take seed. HB 4900 fails to do either.

2017 AAM Annual Report

2017 Was Epic

The landscape around us looks much different today than it did just one year ago. As our industry changes within the evolving pharmaceutical ecosystem, we must speak with one voice to drive home the message that a robust generic drug and biosimilars marketplace is necessary to sustain affordable health care.

AAM Continues to Build Its State Government Affairs Team

WASHINGTON DC (NOVEMBER 6, 2017) – Brett Michelin and Ashlie Van Meter are joining the Association for Accessible Medicines’ (AAM) State Government Affairs team as Director and Senior Director, respectively.

"We are excited to welcome Ashlie and Brett to the AAM team," says Carrie Hartgen, Vice President, State Government Affairs. "The depth and breadth of their experience in government affairs will be an asset to AAM's state affairs department."

Subscribe to State Initiatives

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.